Scandinavian ChemoTech AB (publ) (CMOTEC-B.ST)
SEK 1.33
(-4.68%)
SEK 1.33
(-4.68%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.83 Million SEK | -50.21% |
| 2022 | 7.7 Million SEK | 307.24% |
| 2021 | 1.89 Million SEK | -71.98% |
| 2020 | 6.75 Million SEK | -12.95% |
| 2019 | 7.76 Million SEK | 235.5% |
| 2018 | 2.31 Million SEK | -9.52% |
| 2017 | 2.55 Million SEK | 13.94% |
| 2016 | 2.24 Million SEK | -61.21% |
| 2015 | 5.78 Million SEK | 29367.34% |
| 2014 | 19.62 Thousand SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 11.84 Million SEK | 42.27% |
| 2024 Q1 | 8.32 Million SEK | 116.86% |
| 2023 Q2 | 9.36 Million SEK | 12.81% |
| 2023 FY | 3.83 Million SEK | -50.21% |
| 2023 Q4 | 3.83 Million SEK | -62.32% |
| 2023 Q1 | 8.3 Million SEK | 7.67% |
| 2023 Q3 | 10.18 Million SEK | 8.78% |
| 2022 Q1 | 1.51 Million SEK | -19.76% |
| 2022 FY | 7.7 Million SEK | 307.24% |
| 2022 Q3 | 11.07 Million SEK | 85.24% |
| 2022 Q4 | 7.7 Million SEK | -30.37% |
| 2022 Q2 | 5.97 Million SEK | 293.48% |
| 2021 Q3 | 1.73 Million SEK | -54.03% |
| 2021 FY | 1.89 Million SEK | -71.98% |
| 2021 Q2 | 3.78 Million SEK | 193.03% |
| 2021 Q4 | 1.89 Million SEK | 8.86% |
| 2021 Q1 | 1.29 Million SEK | -80.89% |
| 2020 Q3 | 7.23 Million SEK | -1.98% |
| 2020 Q1 | 10.67 Million SEK | 37.54% |
| 2020 FY | 6.75 Million SEK | -12.95% |
| 2020 Q2 | 7.37 Million SEK | -30.87% |
| 2020 Q4 | 6.75 Million SEK | -6.6% |
| 2019 Q4 | 7.76 Million SEK | 6.86% |
| 2019 FY | 7.76 Million SEK | 235.5% |
| 2019 Q3 | 7.26 Million SEK | 158.25% |
| 2019 Q2 | 2.81 Million SEK | 47.53% |
| 2019 Q1 | 1.9 Million SEK | -17.6% |
| 2018 FY | 2.31 Million SEK | -9.52% |
| 2018 Q2 | 5.93 Million SEK | 233.56% |
| 2018 Q1 | 1.78 Million SEK | 0.0% |
| 2018 Q3 | 1.79 Million SEK | -69.81% |
| 2018 Q4 | 2.31 Million SEK | 28.98% |
| 2017 Q2 | 2.24 Million SEK | 12.77% |
| 2017 FY | 2.55 Million SEK | 13.94% |
| 2017 Q1 | 1.98 Million SEK | -49.38% |
| 2017 Q3 | 2.4 Million SEK | 7.07% |
| 2016 Q4 | 3.93 Million SEK | 0.0% |
| 2016 FY | 2.24 Million SEK | -61.21% |
| 2016 Q2 | 5.78 Million SEK | 0.0% |
| 2015 FY | 5.78 Million SEK | 29367.34% |
| 2015 Q3 | - SEK | 0.0% |
| 2014 FY | 19.62 Thousand SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 99.755% |
| AcouSort AB (publ) | 10.37 Million SEK | 63.018% |
| Active Biotech AB (publ) | 13.4 Million SEK | 71.358% |
| Alzinova AB (publ) | 9.33 Million SEK | 58.868% |
| Amniotics AB (publ) | 10.54 Million SEK | 63.611% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | 13.285% |
| BioArctic AB (publ) | 139.5 Million SEK | 97.249% |
| Camurus AB (publ) | 414.81 Million SEK | 99.075% |
| Cantargia AB (publ) | 54.97 Million SEK | 93.018% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | 72.131% |
| Genovis AB (publ.) | 98.04 Million SEK | 96.086% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | 79.247% |
| Mendus AB (publ) | 51.22 Million SEK | 92.508% |
| Kancera AB (publ) | 17.97 Million SEK | 78.652% |
| Karolinska Development AB (publ) | 11.56 Million SEK | 66.825% |
| LIDDS AB (publ) | 3.75 Million SEK | -2.183% |
| Lipum AB (publ) | 7.53 Million SEK | 49.085% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | 25.591% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 96.904% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -62.696% |
| NextCell Pharma AB | 13.68 Million SEK | 71.963% |
| OncoZenge AB (publ) | 1.69 Million SEK | -125.898% |
| Saniona AB (publ) | 86.08 Million SEK | 95.542% |
| Simris Alg AB (publ) | 148.93 Million SEK | 97.423% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 90.607% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 99.204% |
| Xintela AB (publ) | 14.01 Million SEK | 72.615% |
| Ziccum AB (publ) | 6.38 Million SEK | 39.919% |
| Isofol Medical AB (publ) | 19.16 Million SEK | 79.973% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 94.658% |
| CombiGene AB (publ) | 4.15 Million SEK | 7.652% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 94.603% |
| Intervacc AB (publ) | 21.68 Million SEK | 82.297% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 96.399% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | 88.908% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | 85.63% |
| Corline Biomedical AB | 6.78 Million SEK | 43.467% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 93.745% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | 76.187% |
| Aptahem AB (publ) | 8.99 Million SEK | 57.345% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 91.689% |
| Fluicell AB (publ) | 8.91 Million SEK | 56.949% |
| Biovica International AB (publ) | 34.76 Million SEK | 88.961% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | 67.107% |
| Abliva AB (publ) | 16.78 Million SEK | 77.129% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 98.212% |
| 2cureX AB (publ) | 2.93 Million SEK | -30.767% |
| I-Tech AB | 16.2 Million SEK | 76.316% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 99.676% |
| Cyxone AB (publ) | 4.69 Million SEK | 18.236% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | 71.203% |
| Biosergen AB | 5.08 Million SEK | 24.523% |
| Nanologica AB (publ) | 79.32 Million SEK | 95.162% |
| SynAct Pharma AB | 51.83 Million SEK | 92.596% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | 51.717% |
| BioInvent International AB (publ) | 90.45 Million SEK | 95.757% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | 26.12% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 97.887% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -113.935% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | 69.884% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | 47.135% |